Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
distamycin/leukemija
Veza se sprema u međuspremnik
Stranica 1 iz 39 rezultatima
A new rare distamycin A-inducible fragile site, fra(11) (p15.1), found in two acute nonlymphocytic leukemia (ANLL) patients with t(7;11)(p15-p13;p15).
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Fragile sites were analyzed in normal peripheral lymphocytes from two acute nonlymphocytic leukemia patients with t(7;11)(p15-p13;p15) leukemic cells. To induce expression of fragile sites, cultures were exposed to folate deprivation (M-F10), BrdU, distamycin A, or Hoechst 33258. Fragility at
Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
N-deformyl-N-[4-N,N-bis(2-chloroethylamino)benzoyl] distamycin-A (FCE 24517) is a new cytotoxic anti-tumor agent in phase-1 clinical trials. We have isolated stable FCE-24517-resistant cell sublines from murine leukemia L1210 cells by in vitro exposure to the drug. FCE 24517 selects a mixed
Novel benzoyl nitrogen mustard derivatives of pyrazole analogues of distamycin A: synthesis and antileukemic activity.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The design and synthesis of novel benzoic acid mustard (BAM) derivatives of distamycin A bearing one or more pyrazole rings replacing the pyrrole rings of the latter are described. In vitro and in vivo activities against L1210 leukemia are reported and discussed. Some of these compounds show an
Design, synthesis and biological evaluation of benzoic acid mustard derivatives of imidazole-containing and C-terminal carboxamide analogues of distamycin.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The synthesis, DNA binding and biological evaluation of two benzoic acid mustard derivatives of imidazole-containing analogues of distamycin in which the C-terminus is modified to contain a terminal carboxamide are described. The apparent DNA binding constants of compounds 5 and 6 were determined
Synthesis, DNA binding, cytotoxicity and sequence specificity of a series of imidazole-containing analogs of the benzoic acid mustard distamycin derivative tallimustine containing an alkylating group at the C-terminus.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
In an attempt to produce additional alkylation and crosslinking in the minor groove of DNA, imidazole-containing analogs of distamycin were synthesized with benzoic acid mustard (BAM) and methoxyaziridinyl moieties present at the N- and C-termini, respectively. Analogs 1a-c differed in the number of
Heritable fragile sites and cancer: fra(16)(q22) in lymphocytes of an acute nonlymphocytic leukemia patient with inv(16)(p13q22).
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Fragile site testing was performed on normal peripheral blood lymphocytes from three acute nonlymphocytic leukemia patients who carried inv(16)(p13q22) in malignant cells. Cultures were treated with BrdU, distamycin A, Hoechst 33258, or folic acid deprivation to induce fragile site expression. One
Binding to DNA, cellular uptake and biological activity of a distamycin-ellipticine hybrid molecule.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
A hybrid molecule which conjugates the minor groove binding agent distamycin and an ellipticine derivative was synthesized and evaluated for cytostatic and cytotoxic activities against L1210 leukaemia cells in vitro. The binding of the hybrid molecule, named 'Distel', to a range of natural DNAs and
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Despite progress in leukemia therapy, only 20-30% of patients with acute myelogenous leukemia (AML) are cured. 1-beta-D-arabinofuranosylcytosine- and topoisomerase II-reactive drugs are the primary therapeutic agents used. The aim of this study was to evaluate the potential activity of tallimustine
Distamycin A-inducible fragile sites and cancer proneness.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
To determine the baseline frequency of autosomal rare fragile sites in cancer patients, we conducted a population cytogenetic study of 370 patients with leukemias, solid tumors, and other neoplastic disorders. Twenty carriers of rare fragile sites were detected in this patient group. The rare
Do leukemia patients with chromosome 16 inversion--inv(16)(p13q22)--have a rare fragile site at 16q22?
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Chromosomes were examined in the peripheral blood cells from three cases of acute myelomonocytic leukemia (AMMoL) with inv(16)(p13q22) in order to induce the rare fragile site at 16q22 [fra(16)(q22)] with distamycin-A and berenil. No chromosomal gaps, breaks, or reaRrangements at 16q22 were noted in
[Specific chromosome aberrations in 3 patients with Burkitt-like leukemia (Fab: L3)].
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Karyotype analysis using the Tri-staining-technique (Chromomycin A3/Distamycin A/DAPI) and subsequent DAPI/AMD staining (Schweizer, 1981) was performed on the bone marrow and peripheral blood of three patients with "Burkitt-like" acute lymphatic leukaemia (FAB: L3). In two patients we found the
Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemia.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The secondary constriction region (h) of human chromosome 9 was evaluated in 55 chronic myelogenous leukemia (CML) patients with respect to its size and position. Each case was examined by C-banding and distamycin A-4,6-diamidino-2-phenylindole techniques for the expression of the h regions. When
The mixed lineage leukemia (MLL) protein involved in 11q23 translocations contains a domain that binds cruciform DNA and scaffold attachment region (SAR) DNA.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Translocations involving chromosome band 11q23, found in acute lymphoid and myeloid leukemias, disrupt the MLL gene. This gene encodes a putative transcription factor with regions of homology to several other proteins including the zinc fingers and other domains of the Drosophila trithorax gene
Synthesis and preliminary cytotoxicity of nitrogen mustard derivatives of distamycin A.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Distamycin and nitrogen mustard conjugates, in which the nitrogen mustard unit was coupled to the C-terminus of the pyrrole, were synthesized. The switching of the nitrogen mustard unit from the N-terminus to the C-terminus did not compromise the compound's cytotoxicity. Compound 3, bearing three
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The design, synthesis, and in vivo and in vitro antileukemic activity of a novel series of compounds (13-22 and 34), in which different benzoheterocyclic rings, bearing a nitrogen mustard or a benzoyl nitrogen mustard or an alpha-bromoacryloyl group as alkylating moieties, are tethered to a
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
